The mean age at diagnosis was 0·5 years (SD 0·4) for those with SMA type 1, 1·6 years (SD 0·8) for those with SMA type 2, and 2·9 years (SD 1·7) for those with SMA type 3. As of data cutoff (Nov 1, ...
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
Evrysdi is the only non-invasive disease-modifying treatment for SMA. The 5 mg Evrysdi tablet can either be swallowed whole or dispersed in water. “Evrysdi has robust potential to modify the SMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback